

4/9/1

012917904 \*\*Image available\*\*

WPI Acc No: 2000-089740/200008

XRAM Acc No: C00-025123

**Micronization of medicaments to improve homogeneity and bioavailability of active compound**

Patent Assignee: GUERRY A (GUER-I); LOUZIER R (LOUZ-I)

Inventor: GUERRY A; LOUZIER R

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week
FR 2779347	A1	19991210	FR 987057	A	19980605	200008 B

Priority Applications (No Type Date): FR 987057 A 19980605

Patent Details:

Patent No Kind Lan Pg Main IPC Filing Notes

FR 2779347 A1 6 A61K-031/215

Abstract (Basic): FR 2779347 A1

NOVELTY - The micronization of medicaments comprises micronizing fenofibrate (isopropyl 2-(4-(4-chlorobenzoyl)-phenoxy)-2-methyl-propionate) in a tank (1) under resonance by a passive oscillating system comprising a mechanical vibrator (5), a parabolic reflector (10) on a spring (11), a periodic emitter (9) activated by generators (8) and (6).

USE - Useful for micronizing pharmaceutical formulations, especially capsules comprising fenofibrate.

ADVANTAGE - The formulation has an improved homogeneity and fenofibrate has an improved bioavailability in vivo.

DESCRIPTION OF DRAWING(S) - The drawing shows a schematic view of the apparatus for preparing the fenofibrate capsules.

Tank (1)

Inlet pipes (2-4)

Mechanical vibrator (5)

Generators (6,8)

Outlet pipe (7)

Periodic emitter (9)

Parabolic reflector (10)

pp; 6 DwgNo 1/1

Technology Focus:

TECHNOLOGY FOCUS - MECHANICAL ENGINEERING - Preferred Apparatus:

Pipes (2), (3) and (4) are connected to the tank (1) to feed the fenofibrate which will be micronized by the passive oscillating system (3), the parabolic reflector (10) and the periodic emitter (9), in order to obtain fenofibrate particles of less than 1 microns.

Monohydrated lactose (1 %) and starch (0.3 %) are added to the micronized fenofibrate and the mixture was granulated with water (8.9 %) in the tank (1). The mixture is dried and calibrated into granules of less than 1000 microns. Polyvinylpyrrolidone and magnesium stearate are added. The obtained homogenized powder is discharged from the tank (1) through the pipe (7), dried and placed into capsules.

Title Terms: MEDICAMENT; IMPROVE; HOMOGENEOUS; ACTIVE; COMPOUND

Derwent Class: B07

International Patent Class (Main): A61K-031/215

International Patent Class (Additional): A61K-009/14; B01F-011/02

File Segment: CPI

Manual Codes (CPI/A-N): B10-F02; B11-C05; B12-M11C

Chemical Fragment Codes (M1):

\*03\* M423 M431 M782 M904 M905 M910 N103 N104 R01863-K R01863-M

\*04\* F012 F013 F423 H7 H715 H721 J5 J521 L9 L941 M210 M212 M240 M281 M320  
M423 M431 M510 M521 M530 M540 M782 M904 M905 N103 N104 RA00D5-K

RA00D5-M

## Chemical Fragment Codes (M2):

\*01\* G013 G019 G100 H5 H541 H6 H602 H641 H8 J0 J011 J2 J271 J5 J581 M1  
M121 M131 M150 M210 M213 M232 M272 M281 M313 M321 M331 M340 M342  
M349 M381 M391 M414 M431 M510 M520 M532 M540 M782 M904 M905 N103  
N104 R07499-K R07499-M

\*02\* F012 F013 F014 F015 F016 F123 H4 H405 H423 H484 H5 H521 H8 J4 J471  
K0 L8 L814 L815 L822 L831 M280 M311 M315 M321 M332 M342 M344 M349  
M373 M381 M391 M413 M431 M510 M521 M530 M540 M782 M904 M905 M910  
N103 N104 R00241-K R00241-M

## Chemical Fragment Codes (M6):

\*06\* M905 R031 R501 R534 R536

Derwent Registry Numbers: 0241-U; 1863-U

Specific Compound Numbers: R07499-K; R07499-M; R00241-K; R00241-M; R01863-K  
; R01863-M; RA00D5-K; RA00D5-M; R01376-K; R01376-M

## Key Word Indexing Terms:

\*01\* 56978-2-0-0-CL 107779-0-0-0-CL 1062-0-0-0-CL 95021-0-0-0-CL  
2021-0-1-0-CL, ST

Derwent WPI (Dialog® File 351): (c) 2002 Thomson Derwent. All rights reserved.

---

© 2002 The Dialog Corporation